Lung Cancer Interception/INTIME Dream Team - Stand Up To Cancer

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Lung Cancer Interception/INTIME Dream Team

SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team:
Intercept Lung Cancer Through Immune, Imaging, and Molecular Evaluation (InTIME)

Grant Term: March 2018–February 2022

With innovative technologies and unique patient populations, the SU2C–LUNGevity Foundation–American Lung Association (ALA) Lung Cancer Interception Dream Team seeks to understand how early lung cancer develops and is testing methods to block this development using several complementary approaches. The insights gained from this team’s work will enable the medical and research communities to make major strides in the effort to thwart lung cancer before it occurs.

Supported by:

ABOUT THIS TEAM’S RESEARCH

Lung cancer is the leading cause of cancer death in the United States and worldwide. The SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team proposes several complementary strategies to help prevent patients from developing lung cancer.

The team is working to create an atlas of precancer of the lung that can help identify the types of cancerous lung tissue that will require aggressive treatment. The team is also attempting to identify treatments that can prevent these abnormal lesions from progressing to invasive lung cancer.

In addition, the researchers are developing two sets of diagnostic tools that will be able to detect lung cancer early. The first set involves using nasal swabs and imaging to confirm whether lung abnormalities found in chest images are lung cancer or benign lung characteristics. The second set involves the use of blood tests to identify patients at the earliest stages of lung cancer recurrence.

SEE SCIENTIFIC ABSTRACT

MEET THE TEAM

The top scientists and researchers on the SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team.

Avrum Spira, MD
Leader
Boston Medical Center Cancer Center
LEARN MORE
Steven M. Dubinett, MD
Co-leader
University of California, Los Angeles
LEARN MORE

Dream Team Members

Avrum Spira, MD
Boston Medical Center Cancer Center
Leader

Steven Dubinett, MD
University of California, Los Angeles
Co-leader

Carina Mari Aparici, MD
Stanford University
Principal Investigator

Julie Brahmner, MD
Johns Hopkins University
Principal Investigator

Matthew Meyerson, MD, PhD
Dana-Farber Cancer Institute
Principal Investigator

Charles Swanton, MBBS
Francis Crick Institute
Principal Investigator

Marcia Horn
International Cancer Advisory Network (ICAN)
Advocate

Kim Norris
Lung Cancer Foundation of America
Advocate

Ipsita Dey-Guha, PhD
Boston University School of Medicine
Project Manager

“
”

“We plan to develop technology that can, in a very sensitive way, pick up the small amount of DNA that might be present in the blood of someone who’s harboring a lung cancer deep within their lung tissue—a noninvasive way of measuring a person’s risk of having lung cancer.”

Avrum Spira, MD
Boston Medical Center Cancer Center

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click below to see summaries of research results so far for the SU2C–LUNGevity Foundation–ALA Lung Cancer Interception Dream Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

Single-cell characterization of subsolid and solid lesions in the lung adenocarcinoma spectrum.
Yanagawa, J., Tran, L.M., Fung, E., et al.
bioRxiv 2020.12.25.424416; doi: https://doi.org/10.1101/2020.12.25.424416
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small cell lung cancer.
Anagnostou V, Niknafs N, Marrone K, et al.
Nat Cancer. 2020 Jan;1(1):99-111. doi: 10.1038/s43018-019-0008-8.
Organoids model transcriptional hallmarks of oncogenic KRAS activation in lung epithelial progenitor cells.
Dost AFM, Moye AM, Vedaie M, Tran LM, et al.
Cell Stem Cell. 2020 Oct 1;27(4):663-678.e8. doi: 10.1016/j.stem.2020.07.022.
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
Rozenblatt-Rosen O, Regev A, Oberdoerffer P, et al.
Cell. 2020;181(2):236‐249. doi:10.1016/j.cell.2020.03.053Cell Stem Cell, accepted.
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
Abdul Jabbar K, Raza SEA, Rosenthal R, et al.
Nat Commun. 2019 Nov 29;10(1):5472. doi: 10.1038/s41467-019-13460-3.
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.
Ghorani, E., Reading, J.L., Henry, J.Y. et al.
Nat Cancer. 2020; 1, 546–561. https://doi.org/10.1038/s43018-020-0066-y.
Genomic and immune profiling of pre-invasive lung adenocarcinoma.
Chen H, Carrot-Zhang J, Zhao Y, et al.
Nat Commun. 2019 Nov 29;10(1):5472. doi: 10.1038/s41467-019-13460-3.
TRACERx Consortium. A clonal expression biomarker associates with lung cancer mortality.
Biswas D, Birkbak NJ, Rosenthal R, et al.
Nat Med. 2019 Oct;25(10):1540-1548. doi: 10.1038/s41591-019-0595-z.
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Joshi K, Robert de Massy M, Ismail M, et al.
Nat Med. 2019 Oct;25(10):1549-1559. doi: 10.1038/s41591-019-0592-2. Epub 2019 Oct 7.
Early Stage NSCLC — Challenges to Implementing ctDNA-Based Screening and MRD Detection
Abbosh C, Birkbak NJ, Swanton C (2018)
Nat Rev Clin Oncol. 15(9):577-586.
Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer
Phallen J, Leal A, Woodward BD, et al (2018)
Cancer Res. pii: canres.1082.2018.
Dynamics of Tumor and Immune Responses During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Anagnostou V, Forde PM, White JR, et al (2018)
Cancer Res. pii: canres.1127.2018.
See MoreLess Publications

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find clinical trial information, answers to common questions, and a free clinical trial finder tool.

LEARN MORE

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.